Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) infections were first detected in hospitals (healthcareacquired/associated (HA) MRSA). However, in recent years infections have emerged in the community (communityacquired/associated (CA) MRSA) and also from livestock (livestock-associated (LA) MRSA). Consequently, MRSA can no longer be considered an exclusive healthcare-associated problem and it cannot be fought by hospital infection prevention and control measures alone.
1
Most of the antibiotics currently in use can be classified as follows: β -lactam and glycopeptide antibiotics targeting cell wall biosynthesis; aminoglycoside, tetracycline, and macrolide antibiotics targeting protein synthesis; and fluoroquinolones targeting DNA gyrase and topoisomerase. To tackle the problem of drug resistance, one can focus on these proven targets and develop new drugs to overcome drug-induced resistance caused by mutations of the targets or modifications of the antibiotics.
2
In our previous papers, we have reported the synthesis of some 2-phenyl-1H -benzimidazole derivatives (I, II, III, Figure) and their promising antimicrobial activities.
3−6 These results prompted us to investigate a series of new 2-[4-(1 H -benzimidazol-1-yl)phenyl]-1H -benzimidazoles to evaluate their antistaphylococcal and antifungal activities.
Results and discussion
All the benzimidazole compounds prepared herein were screened for their potential in vitro antibacterial activities against S. aureus, MRSA, and antifungal activities against Candida albicans. The in vitro minimal inhibitory concentrations (MIC 100 ) of the compounds were determined using the microbroth dilution method reported by the National Committee for Clinical Laboratory Standards. 
NH
Figure.
Structures of previously reported benzimidazoles possessing antibacterial activities.
Table.
Formula and in vitro antimicrobial activities for 13-22.
-22
No.
Antimicrobial activities (MIC, µg/mL) S. aureus MRSA C. albicans ATCC25923 ATCC43300 ATCC10231 10 were synthesized as described in the literature.
Chemistry
The synthetic pathway for the preparation of the targeted benzimidazoles 13-22 is shown in the Scheme. The 1 H -benzimidazole (2) was built by cyclization of o -phenylenediamine (1) 
General synthesis of 13-22
A mixture of commercial o-phenylendiamines 1, 4-12 (1 mmol), 1-(4-formylpheny)-1H-benzimidazole (3) (1 mmol), and Na 2 S 2 O 5 (1 mmol) in DMF (3 mL) was heated at 110-120
• C for 3 h. 14 The reaction mixture was cooled, poured into H 2 O, and the solid was filtered. The residue was purified by column chromatography using chloroform/methanol (100:10) as eluant.
2-[4-(1H -Benzimidazol-1-yl)phenyl]-1H -benzimidazole 13
Yield 48%, mp 199-200 
2-[4-(1H -Benzimidazol-1-yl) phenyl]-5(6)-methyl-1H -benzimidazole 14

2-[4-(1H -Benzimidazol-1-yl)phenyl]-1H -benzimidazole-5(6)-carbonitrile 15
Yield 35%, mp 333-335 
2-[4-(1H -Benzimidazol-1-yl)phenyl]-1H -benzimidazole-5(6)-carboxylic acid 16
Yield 56%, mp 344-346 
2-[4-(1H -Benzimidazol-1-yl)phenyl]-5(6)-nitro-1H -benzimidazole 17
Yield 36%, mp 313-315 
2-[4-(1H -Benzimidazol-1-yl)phenyl]-5(6)-chloro-1H -benzimidazole 18
Yield 25%, mp 88
• C (bubb.) 268 
2-[4-(1H -Benzimidazol-1-yl)phenyl]-5(6)-fluoro-1H -benzimidazole 19
Yield 30%, mp 267-268 
